Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Lymphoid 3Genitourinary 3Other hematologic neoplasm 2Dermatologic 2Gastrointestinal 1

Conditions

Melanoma, Cutaneous Malignant 1Melanoma 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Cholecalciferol × Dermatologic × Clear all
NCT01748448 2025-02-17

ViDMe

Universitaire Ziekenhuizen KU Leuven

Phase 3 Completed
436 enrolled 16 charts
Dermatologic

Melanoma, Cutaneous Malignant

NCT01264874 2018-01-31

MelaViD

European Institute of Oncology

Phase 3 Terminated
150 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡